Treatment of heart failure beyond practice guidelines: Role of cardiac remodeling

Circulation Journal

Volumn 72, Issue SUPPL. A, 2008, Pages

  Misra, Arunima ^a   Mann, Douglas L ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS HEART INSTITUTE   (United States)

Author keywords

Guidelines; Heart failure; Neurohumoral activation; Remodeling

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

CARDIAC SUPPORT DEVICE; DEVICE; DISEASE COURSE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HEART VENTRICLE REMODELING; HUMAN; MORBIDITY; MORTALITY; PACEMAKER; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW;

DISEASE PROGRESSION; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; NEUROTRANSMITTER AGENTS; PRACTICE GUIDELINES AS TOPIC; VENTRICULAR REMODELING;

EID: 52949110126     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0661     Document Type: Review

References (35)

1. Mann DL. Mechanisms and models in heart failure: A combinatorial approach. Circulation 1999; 100: 999-1088.
2. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
3. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327: 685-691.
4. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-2816.
5. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler M, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1350-1355.
6. Mann DL, Bristow MR. Mechanisms and models in heart failure: The biomechanical model and beyond. Circulation 2005; 111: 2837-2849.
7. Cohn JN. Structural basis for heart failure: Ventricular remodeling and its pharmacological inhibition. Circulation 1995; 91: 2504-2507.
8. Douglas PS, Morrow R, Ioli A, Reicheck N. Left ventricular shape, afterload, and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1989; 13: 311-315.
9. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 1997; 336: 1350-1355.
10. Tsutsui H, Spinale FG, Nagatsu M, Schmid PG, Ishihara K, DeFreyte G, et al. Effects of chronic β-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest 1994; 93: 2639-2648.
11. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995; 25: 1154-1161.
12. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1998; 29: 1060-1066.
13. Sabbah HN, Sharov VG, Gupta RC, Mishra S, Rastogi S, Undrovinas AI, et al. Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. CircRes 2003; 93: 1095-1101.
14. Linzbach AJ. Heart Failure from the point of view of quantitative anatomy. Am J Cardiol 1960; 5: 370-382.
15. Ross J Jr. Afterload mismatch in aortic and mitral valve disease: Implications for surgical therapy. J Am Coll Cardiol 1985; 5: 811-826.
16. Ross J Jr. Mechanisms of cardiac contraction: What roles for preload, afterload and inotropic state in heart failure? Eur Heart J 1983; 4(Suppl A): 19-28.
17. Hirota Y, Saito T, Kita Y, Shimizu G, Kino M, Kawamura K. The natural history of dilated cardiomyopathy and pathophysiology of congestive heart failure. J Cardiogr Suppl 1986; 9: 67-76 (in Japanese).
18. Pouleur H, Rousseau MF, van Eyll C, Melin J, Youngblood M, Yusuf S. Cardiac mechanics during development of heart failure: SOLVD Investigators. Circulation 1993; 87(Suppl): IV-14-IV-20.
19. Vatner SF. Reduced subendocardial myocardial perfusion as one mechanism for congestive heart failure. Am J Cardiol 1988; 62: 94E-98E.
20. Shannon RP, Komamura K, Shen YT, Bishop SP, Vatner SF. Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure. Am J Physiol 1993; 265: H801-H809.
21. LeGrice IJ, Takayama Y, Holmes JW, Covell JW. Impaired subendocardial function in tachycardia-induced cardiac failure. Am J Physiol 1995; 268: H1788-H1794.
22. Kapadia S, Oral H, Lee J, Nakano M, Taffet GE, Mann DL. Hemo-dynamic regulation of tumor necrosis factor-α gene and protein expression in adult feline myocardium. Circ Res 1997; 81: 187-195.
23. Sadoshima JI, Xu Y, Slayter HS, Izumo S. Autocrine release of angio-tensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993; 75: 977-984.
24. Ruwhof C, Van der LA. Mechanical stress-induced cardiac hypertrophy: Mechanisms and signal transduction pathways. Cardiovasc Res 2000; 47: 23-37.
25. Batista R. Partial left ventricularectomy: The Batista procedure. Eur J Cardiothorac Surg 1999; 15(Suppl I): S12-S19.
26. Dor V, Saab M, Coste P, Kornaszewska M, Montiglio F. Left ventricular aneurysm: A new surgical approach. Thorac Cardiovasc Surg 1989; 37: 11-19.
27. Kass DA, Baughman KL, Pak PH, Cho PW, Levin HR, Gardner TJ, et al. Reverse remodeling from cardiomyoplasty in human heart failure: External constraint versus active assist. Circulation 1995; 91: 2314-2318.
28. Starling RC, McCarthy PM, Yamini MH. Surgical treatment of chronic congestive heart failure. In: Mann DL, editor. Heart failure: A companion to Braunwald's heart disease, 1st edn. Philadelphia: Saunders; 2003; 717-736.
29. Saavedra WF, Tunin RS, Paolocci N, Mishima T, Suzuki G, Emala CW, et al. Reverse remodeling and enhanced adrenergic reserve from passive external support in experimental dilated heart failure. J Am Coll Cardiol 2002; 39: 2069-2076.
30. Chaudhry PA, Mishima T, Sharov VG, Hawkins J, Alferness C, Paone G, et al. Passive epicardial containment prevents ventricular remodeling in heart failure. Ann Thorac Surg 2000; 70: 1275-1280.
31. Oz MC, Konertz WF, Kleber FX, Mohr FW, Gummert JF, Ostermeyer J, et al. Global surgical experience with the Acorn cardiac support device. J Thorac Cardiovas Surg 2003; 126: 983-991.
32. Mann DL, Acker MA, Jessup M, Sabbah HN, Starling RC, Kubo SH. Clinical evaluation of the CorCap Cardiac Support Device in patients with dilated cardiomyopathy. Ann Thorac Surg 2007; 84: 1226-1235.
33. Starling RC, Jessup M, Oh JK, Sabbah HN, Acker MA, Mann DL, et al. Sustained benefits of the CorCap Cardiac Support Device on left ventricular remodeling: Three year follow-up results from the Acorn clinical trial. Ann Thorac Surg 2007; 84: 1236-1242.
34. Klodell CT Jr, Aranda JM Jr, McGiffin DC, Rayburn BK, Sun B, Abraham WT, et al. Worldwide surgical experience with the Paracor HeartNet cardiac restraint device. J Thorac Cardiovas Surg 2008; 135: 188-195.
35. Klodell CT Jr, McGiffin DC, Rayburn BK, Sun B, Abraham WT, Conte JV, et al. Initial United States experience with the Paracor HeartNet myocardial constraint device for heart failure. J Thorac Cardiovas Surg 2007; 133: 204-209.